Long-term efficacy is maintained through functional melanoma-specific CD8+ memory T cells, which persist in various locations such as skin, lymph nodes and the bloodstream—even after complete resection of the primary tumor and affected TDLNs. The gene discussed is CD8A; the disease is melanoma.